{
  "docId": "019de076-906b-74a9-92f8-5c2872231d60",
  "docSlug": "a8776e7183e96a109d1a49143fc2ff88",
  "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 26 slides",
  "authorId": "arbutus-biopharma",
  "authorName": "Arbutus Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 26,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide outlines a clinical trial protocol with specific patient counts (n=12, n=8) and timeline milestones (weeks 1, 24, 28, 40, 52).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-906b-74a9-92f8-5c2872231d60/14",
  "deckHref": "/decks/019de076-906b-74a9-92f8-5c2872231d60",
  "deckJsonHref": "/decks/019de076-906b-74a9-92f8-5c2872231d60.json",
  "deckAnchorHref": "/decks/019de076-906b-74a9-92f8-5c2872231d60#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.6,
        "x": 0.35,
        "y": 0.1
      },
      "kind": "diagram",
      "text": "Clinical trial timeline showing randomization at week 24, treatment arms, and follow-up periods.",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "59247d45-0da4-40e6-b1d4-b1bc0829fbe5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.65,
        "x": 0.3,
        "y": 0.85
      },
      "kind": "paragraph",
      "text": "Preliminary data through 12 weeks of IFN treatment for the first 12 subjects were presented at EASL Congress 2023",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "227eed89-0c8a-4455-9bcf-48f7c3bf9b21",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.65,
        "x": 0.3,
        "y": 0.65
      },
      "kind": "paragraph",
      "text": "Primary objective: evaluate safety and tolerability of imdusiran in combination with Peg-IFNα-2a in patients with NA-suppressed cHBV",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "393124c0-5850-4c59-a2e3-ece61a048f18",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.05,
        "y": 0.5
      },
      "kind": "paragraph",
      "text": "Imdusiran in combination with ongoing NA therapy and short courses of Peg-IFNα-2a in cHBV patients",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5174d5e0-a0c0-46ae-a00a-a1f6da58cbdf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.65,
        "x": 0.3,
        "y": 0.75
      },
      "kind": "paragraph",
      "text": "After 24-weeks of follow-up, patients are assessed to stop NA therapy. Those patients that stop NA therapy will be followed for an additional 48 weeks.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dca326cc-9ebc-46db-b195-a60a9939930f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.25,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "title",
      "text": "AB-729-201: Phase 2a POC Clinical Trial",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0a8eea92-6afc-48df-ba28-17629c52630e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "573c4dfc-f18a-4ad1-8601-510cba9a60c4",
      "evidence": "The timeline visualization of clinical trial phases and patient cohorts.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 26,
      "from": 8,
      "beatId": "b0891741-a256-4e4e-a8d2-65a9f9895b7f",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents Arbutus Biopharma's pipeline and clinical trial results as a solution.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    },
    {
      "to": 18,
      "from": 11,
      "beatId": "bb704643-20a7-459a-9df1-5b5cea9225d9",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "The document presents clinical trial results and data.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 18,
      "from": 11,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "9268b1b4-494b-44ee-8454-6a997fc0aa8b",
      "evidence": "The document presents clinical trial results and data.",
      "position": 1,
      "objective": "Can Imdusiran RNAi therapeutic and AB-101 oral PD-L1 inhibitor provide a quick win or a big bet for investors?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}